



13th February, 2017

To, The Manager, Listing Department, National Stock Exchange of India Ltd. "Exchange Plaza", C-1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. Ref. : (i) Symbol – DISHMAN (ii) Series – EQ	To, Department of Corporate Services Bombay Stock Exchange Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. Ref. : i) Scrip Code No. : 532526 ii) Debt Scrip Code No. : 946682
---	---

SUB.: ANNOUNCEMENT – Outcome of the Today's Board Meeting - Disclosure Under Regulation 30 and Regulation 33 SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

i) UN-AUDITED FINANCIAL RESULTS ALONGWITH STATUTORY AUDITORS' LIMITED REVIEW REPORT FOR THE QUARTER ENDED 31/12/2016

ii) DECLARATION OF INTERIM DIVIDEND

REF.: i) OUR LETTER DATED 4TH FEBRUARY, 2017 REGARDING INTIMATION OF BOARD MEETING UNDER REGULATION 29

Dear Sir,

As per Regulation 30 of SEBI (LODR) Regulations, 2015 we hereby inform that a Meeting of the Board of Directors of the Company was held today i.e. on Monday, 13th February, 2017 which was commenced at 01:00 PM and concluded at 03:15 PM at 301, 3rd Floor, "Samudra Annexe", Nr. Klassic Gold Hotel, Off. C. G. Road, Navrangpura, Ahmedabad – 380 009, *inter alia*, to consider and take on record the Unaudited Financial Results of the Company for the quarter ended on 31st December, 2016, prepared in terms of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 AND to consider and declare interim dividend on equity shares of the Company for the financial year 2016-17.

At the said Board Meeting, among others, the following decisions were taken by the Board of Directors of the Company:

- 1) The Board has taken on record Unaudited Financial Results of the Company alongwith Statutory Auditors' Limited Review Report dated 13th February, 2017 signed by M/s. V. D. Shukla & Co. and M/s. Haribhakti & Co. LLP, Chartered Accountants, Joint Statutory Auditors of the Company for the quarter ended on 31st December, 2016. (Copy of Unaudited Financial Results of the Company alongwith Statutory Auditors' Limited Review Report are enclosed herewith for your reference)
- 2) The Board has declared an Interim dividend at **60% (i.e. Rs.1.20 per equity share of Rs.2.00 each)** on 16,13,94,272 equity shares of the Company for the financial year 2016-

Dishman Pharmaceuticals and Chemicals Limited


Registered Office: Bhadr-Raj Chambers, Swastik Cross Roads, Navrangpura, Ahmedabad – 380 009 India

Tel: +91 (0) 79 26443053 / 26445807 Fax: +91 (0) 79 26420198

Email: dishman@dishmangroup.com Web: www.dishmangroup.com

Government Recognised Export House

CIN NO L24230GJ1983PLC006329





2017 and Company has fixed **21st February, 2017** as the Record Date for the purpose of Payment of Interim Dividend for the financial year 2016-17.

- 3) The interim dividend shall be paid to the members entitled thereto, on and from 25th February, 2017. The Dividend cheques/warrants would be posted on or after 25th February, 2017 and within 30 days from the date of declaration of interim dividend as provided in the Companies Act, 2013.

Kindly take this on your record.

Thanking you.

Yours faithfully,

For, Dishman Pharmaceuticals and Chemicals Limited

S. G. Dave
Shrima Dave
Company Secretary



Encl.: As above

Dishman Pharmaceuticals and Chemicals Limited

Registered Office: Bhadr-Raj Chambers, Swastik Cross Roads, Navrangpura, Ahmedabad – 380 009 India.

Tel: +91 (0) 79 26443053 / 26445807 Fax: +91 (0) 79 26420198

Email: dishman@dishmangroup.com Web: www.dishmangroup.com

Government Recognised Export House

CIN NO L24230GJ1983PLC006329

Haribhakti & Co. LLP
Chartered Accountants
705, Leela Business Park,
Andheri Kurla Road,
Andheri (East),
Mumbai - 400 059.

V.D.Shukla & Co.
Chartered Accountants
22, Akruvi Society,
New Jodhpur Cross Roads,
Satellite,
Ahmedabad - 380 015.

Limited Review Report

Review Report to

To the Board of Directors


Dishman Pharmaceuticals and Chemicals Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Dishman Pharmaceuticals and Chemicals Limited ('the Company') for the quarter ended December 31, 2016 ('the Statement'), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. CIR/CFD/CMD/15/2015 dated November 30, 2015 and Circular No. CIR/CFD/FAC/ 62/2016 dated July 5, 2016.
2. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" as prescribed under Section 133 of Companies Act, 2013 ("the Act") read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of the Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with aforesaid accounting standards and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No.CIR/CFD/CMD/15/2015 dated November 30, 2015 and Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We draw attention to Note 11 of the Statement, wherein as stated, the Hon'ble High Court of Gujarat has sanctioned the Scheme of Arrangement and Amalgamation amongst the Company, Carbogen Amcis (India) Limited and Dishman Care Limited and their respective Shareholders & Creditors ("Scheme") on 16th December, 2016 and certified copy of the Order alongwith the Scheme is awaited. Pending filing of the Scheme with Registrar of Companies, no impact of the Scheme has been given in books of account. Our report is not modified in respect of this matter.
6. The previously issued financial information of the Company for the quarter and nine months ended December 31, 2015 prepared in accordance with the Companies (Accounting Standard) Rules, 2006 have been restated to comply with Indian Accounting Standards ("Ind AS") and included in the Statement as comparative financial information. Adjustments made to previously issued financial information prepared in accordance with the Companies (Accounting Standard) Rules, 2006 to comply with Ind AS have been reviewed by us.

For Haribhakti & Co. LLP
Chartered Accountants
ICAI Firm Registration No.103523W/W100048



Bhavik L. Shah
Partner
Membership No.: 122071
Mumbai
February 13, 2017



For V.D.Shukla & Co.
Chartered Accountants
ICAI Firm Registration No.110240W



Vimal D. Shukla
Partner
Membership No.: 036416
Ahmedabad
February 13, 2017



DISHMAN PHARMACEUTICALS AND CHEMICALS LIMITED



CIN : L24230GJ1983PLC006329 Email ID : dishman@dishmangroup.com Web : www.dishmangroup.com

Bhadr-Raj Chambers, Swastik Cross Roads, Navrangpura, Ahmedabad-380 009 Phone No : 079-26443053 Fax No : 079-26420198

Part I : Statement of Unaudited Standalone / Consolidated Results for Quarter and Nine Months Ended 31-12-2016

(Rupees in Crores / in Ten Million)

Sr. No.	PARTICULARS	STANDALONE				
		For The Quarter ended 31-12-2016	For The Preceding Quarter ended 30-09-2016	For The Corresponding Quarter ended 31-12-2015	For The Nine Months ended 31-12-2016	For The Corresponding 9 Months ended 31-12-2015
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited
1	Income From Operations					
	a) Net sales/income from operations	96.66	112.96	119.45	294.86	353.35
	b) Other Operating Income	4.83	7.52	10.82	19.71	17.59
	Total Income from operations (net)	101.49	120.48	130.27	314.57	370.94
2	Expenses					
	a) Cost of material consumed	32.54	37.03	41.53	102.76	133.70
	b) Purchase of stock-in-trade	8.61	0.00	5.83	8.67	5.83
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(9.26)	(0.45)	2.35	(17.88)	11.42
	d) Employee benefits expense	18.37	19.87	17.12	53.65	47.45
	e) Depreciation and amortisation expense	11.18	11.48	11.10	33.86	33.38
	f) Other Expenditure	19.12	20.94	20.19	59.23	58.41
	Total expenses	80.56	88.87	98.12	240.29	290.19
3	Profit / (Loss) from Operations before Other Income, finance costs and exceptional items (1-2)	20.93	31.61	32.15	74.28	80.75
4	Other Income	5.54	26.75	2.78	38.35	61.62
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3+4)	26.47	58.36	34.93	112.63	142.37
6	Finance costs	7.46	11.25	14.01	35.94	58.91
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6)	19.01	47.11	20.92	76.69	83.46
8	Exceptional Items	-	-	-	-	-
9	Profit/(Loss) from Ordinary Activities before tax (7+8)	19.01	47.11	20.92	76.69	83.46
10	Tax expense	2.90	9.36	3.90	14.41	19.75
11	Net Profit/(Loss) for the period (9-10)	16.11	37.75	17.02	62.28	63.71
12	Income from Associates	-	-	-	-	-
13	Minority Interest	-	-	-	-	-
14	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (11+12+13)	16.11	37.75	17.02	62.28	63.71
15	Other Comprehensive Income (Net of Tax)	0.51	0.40	(0.08)	0.91	1.39
16	Total Comprehensive Income (After Tax) (14+15)	16.62	38.15	16.94	63.19	65.10
17	Paid -up Equity Share Capital (Face Value of Rs 2/- per equity share)	32.28	32.28	16.14	32.28	16.14
18	Basic and Diluted EPS (before & after Extraordinary Items) (of Rs. 2 each)	-	-	-	-	-
	i) Basic EPS (Not annualised)	1.00	2.34	1.05	3.86	3.95
	ii) Diluted EPS (Not annualised)	1.00	2.34	1.05	3.86	3.95
	See accompanying notes to the financial results					



Haribhakti & Co. LLP
Chartered Accountants
705, Leela Business Park,
Andheri Kurla Road,
Andheri (East),
Mumbai - 400 059.

V.D.Shukla & Co.
Chartered Accountants
22, Akruti Society,
New Jodhpur Cross Roads,
Satellite,
Ahmedabad - 380 015.

Limited Review Report

Review Report to
To the Board of Directors
Dishman Pharmaceuticals and Chemicals Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Dishman Pharmaceuticals and Chemicals Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') and its associates for the quarter ended December 31, 2016 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No.CIR/CFD/CMD/15/2015 dated November 30, 2015 and Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. This Statement which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" as prescribed under Section 133 of Companies Act, 2013 ("the Act") read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and




analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. We believe that the review procedures performed by us and performed by the other auditors in terms of their report referred to in paragraph 7 below, is sufficient and appropriate to provide a basis for our reporting on the Statement.
5. Based on our review conducted as above, on consideration of the reports of the other auditors referred to in paragraph 7 below and based on the consideration of interim financial information furnished to us by the Management referred to in paragraph 8 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with aforesaid accounting standards and other recognised accounting practices and policies have not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No.CIR/CFD/CMD/15/2015 dated November 30, 2015 and Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We draw attention to Note 11 of the Statement, wherein as stated, the Hon'ble High Court of Gujarat has sanctioned the Scheme of Arrangement and Amalgamation amongst the Holding Company, Carbogen Amcis (India) Limited and Dishman Care Limited and their respective Shareholders & Creditors ("Scheme") on 16th December, 2016 and certified copy of the Order alongwith the Scheme is awaited. Pending filing of the Scheme with Registrar of Companies, no impact of the Scheme has been given in books of account. Our report is not modified in respect of this matter.
7. We did not review the financial results of Seven (7) subsidiaries included in the Statement, whose financial results reflect total revenue of ₹ 378.43 Crore and total profit after tax of ₹ 24.96 Crore for the quarter ended December 31, 2016, as considered in the Statement. These financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors.



8. We did not review the financial results of Ten (10) subsidiaries whose financial results reflect total revenue of ₹ 8.05 Crore and total loss after tax of ₹ 6.23 Crore for the quarter ended December 31, 2016, as considered in the Statement. The Statement also includes Group's share of loss after tax of ₹ 0.37 Crore for the quarter ended December 31, 2016, as considered in the Statement, in respect of Two (2) associates, whose financial results have not been reviewed by us. These financial results have not been reviewed by their auditors and have been furnished to us by the Management and our reporting on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and associates is based solely on such un-reviewed financial results. According to the information and explanations given to us by the Management, these financial results are not material to the Group.
9. The consolidated financial results for the quarter and nine months ended 31st December, 2015 have not been reviewed or audited by us and have been presented based on the information compiled by the Management.

For Haribhakti & Co. LLP
Chartered Accountants
ICAI Firm Registration No.103523W/W100048



Bhavik L. Shah
Partner
Membership No.: 122071



Mumbai
February 13, 2017

For V.D.Shukla & Co.
Chartered Accountants
ICAI Firm Registration No.110240W



Vimal D. Shukla
Partner
Membership No.: 036416



Ahmedabad
February 13, 2017

DISHMAN PHARMACEUTICALS AND CHEMICALS LIMITED
CIN : L24230GJ1983PLC006329 Email ID : dishman@dishmangr
Bhadr-Raj Chambers, Swastik Cross Roads, Navrangpura, Ahmedal
Part I : Statement of Unaudited Standalone / Consolidated Results f

(Rupees in Crores / in Ten Million)

Sr. No.	PARTICULARS	CONSOLIDATED				
		For The Quarter ended 31-12-2016	For The Preceding Quarter ended 30-09-2016	For The Corresponding Quarter ended 31-12-2015	For The Nine Months ended 31-12-2016	For The Corresponding 9 Months ended 31-12-2015
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited
1	Income From Operations					
	a) Net sales/income from operations	356.47	426.94	385.98	1,149.30	1,158.91
	b) Other Operating Income	5.60	9.61	6.13	24.72	17.63
	Total Income from operations (net)	362.07	436.55	392.11	1,174.02	1,176.54
2	Expenses					
	a) Cost of material consumed	142.70	68.15	82.31	247.32	274.28
	b) Purchase of stock-in-trade	-	-	-	0.06	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(74.29)	23.69	5.57	(32.94)	(10.45)
	d) Employee benefits expense	130.88	142.97	130.09	418.90	377.17
	e) Depreciation and amortisation expense	29.25	30.89	30.88	88.61	90.57
	f) Other Expenditure	67.09	85.96	61.94	227.05	223.61
	Total expenses	295.63	351.66	310.79	949.00	955.18
3	Profit / (Loss) from Operations before Other Income, finance costs and exceptional items (1-2)	66.44	84.89	81.32	225.02	221.36
4	Other Income	15.53	7.65	(1.26)	30.20	10.66
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3+4)	81.97	92.54	80.06	255.22	232.02
6	Finance costs	13.39	18.90	17.57	54.75	75.43
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6)	68.58	73.64	62.49	200.47	156.59
8	Exceptional Items	-	-	-	-	-
9	Profit/(Loss) from Ordinary Activities before tax (7+8)	68.58	73.64	62.49	200.47	156.59
10	Tax expense	17.53	18.96	17.17	49.24	43.25
11	Net Profit/(Loss) for the period (9-10)	51.05	54.68	45.32	151.23	113.34
12	Income from Associates	(0.37)	-	(0.85)	(0.37)	(0.85)
13	Minority Interest	-	-	0.29	-	-
14	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (11+12+13)	50.68	54.68	44.76	150.86	112.49
15	Other Comprehensive Income (Net of Tax)	(7.47)	(0.22)	21.99	(7.69)	23.28
16	Total Comprehensive Income (After Tax) (14+15)	43.21	54.46	66.75	143.17	135.77
17	Paid-up Equity Share Capital (Face Value of Rs 2/- per equity share)	32.28	32.28	16.14	32.28	16.14
18	Basic and Diluted EPS (before & after Extraordinary Items) (of Rs. 2 each)	-	-	-	-	-
	i) Basic EPS (Not annualised)	3.14	3.39	2.77	9.35	6.97
	ii) Diluted EPS (Not annualised)	3.14	3.39	2.77	9.35	6.97
	See accompanying notes to the financial results					




Segment wise Revenue, Result and Capital Employed						
Sr. No	PARTICULARS	For The Quarter ended 31-12-2016	For The Preceding Quarter ended 30-09-2016	For The Corresponding Quarter ended 31-12-2015	For The Nine Months ended 31-12-2016	For The Corresponding 9 Months ended 31-12-2015
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited
1	Segment Revenue					
	(a) CRAMS	246.70	323.99	292.69	829.30	814.24
	(b) Others	109.77	102.95	93.29	320.00	344.67
	Total	356.47	426.94	385.98	1,149.30	1,158.91
	Less: Inter-segment Revenue	-	-	-	-	-
	Net Sales /Income from Operation	356.47	426.94	385.98	1,149.30	1,158.91
2	Segment Results (Profit/(Loss) before tax and interest from each segment)					
	(a) CRAMS*	48.44	65.33	66.71	164.25	164.73
	(b) Others*	18.00	19.56	14.61	60.77	56.63
	Total	66.44	84.89	81.32	225.02	221.36
	Less: i) Interest	13.39	18.90	17.57	54.75	75.43
	ii) Other un-allocable expenditure net off un-allocable income	(15.53)	(7.65)	1.26	(30.20)	(10.66)
	Total Profit/(Loss) Before Tax	68.58	73.64	62.49	200.47	156.59

* Includes Forex (Loss) / Gain

* For Segmental Capital Employed : Refer Note : 12

Place: Ahmedabad
Date: 13th February, 2017



For and on behalf of the Board

Arpit Vyas
Managing Director and CFO



Notes:



1. The Financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors at their meetings held on 13th February, 2017.
2. Joint Statutory Auditors have carried out a "Limited Review" of the standalone-financial result of the Company for the quarter and nine months ended 31st December, 2016 and 31st December, 2015.
3. Joint Statutory Auditors have carried out a "Limited Review" of the consolidated financial results of the Company for the quarter and nine months ended 31st December, 2016. The figures for the quarter ended December 31, 2016 are the balancing figure between reviewed figures of nine month ended December 31, 2016 and published figures of six months ended September 30, 2016. The consolidated financial results for the quarter and nine months ended 31st December, 2015 have not been reviewed or audited and have been presented based on the information compiled by the Management after making the necessary adjustments to give a true and fair view of the results in accordance with IND AS.
4. As per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, the Company has opted to publish only consolidated financial results. The stand-alone financial results are available for perusal on the Company's website as well as on the stock exchanges' websites as stated below:
www.dishmangroup.com, www.bseindia.com, and www.nseindia.com.
5. As per Indian Accounting Standard ("Ind AS") 108 - "Segment Reporting", segment information has been provided in Consolidated Financial Result.
6. The business segments of the Company comprise the followings:

Segment	Description of the activity
CRAMS	Contract Research and Manufacturing Segment under long term supply agreements
OTHERS	Manufacturing of Bulk Drugs, Intermediates, Quats, Speciality Chemicals, Vitamin D3 analogue and Traded Goods

7. Consolidated financial results comprise the results of the parent Company, Dishman Pharmaceuticals and Chemicals Limited and its subsidiaries viz. Dishman Europe Limited., Dishman USA Inc., Dishman International Trading (Shanghai) Co. Ltd., Dishman Switzerland Limited, CARBOGEN AMCIS Holding AG. (formerly known as "Dishman Pharma Solutions AG"), Switzerland, CARBOGEN AMCIS (Shanghai) Co. Ltd. [formerly known as Dishman Pharmaceuticals & Chemicals (Shanghai) Co. Ltd.], Shanghai Yiqian International Trade Co. Ltd., Innovative Ozone Services Inc. (IO3S), Dishman Netherlands B. V. (formerly known as "Pharma Syn B. V."), Carbogen Amcis Ltd., U.K. (formerly known as "Synprotec DCR Ltd."), CARBOGEN AMCIS AG, Switzerland, Carbogen Amcis (India) Limited, Dishman Australasia Pty. Ltd., Dishman Care Ltd., CARBOGEN AMCIS SAS, Dishman Middle East (FZE), Dishman Japan Limited, and two associate companies namely, Schutz Dishman Biotech Ltd. (22.33% holding by Dishman) and Bhadr-Raj Holdings Pvt. Ltd. (40% holding by Dishman) as per relevant Accounting Standards as at 31st December, 2016.
8. The Company adopted Indian Accounting Standard (Ind AS) from April 1, 2016 and accordingly these financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind As 34 interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued there under and the other accounting principles generally accepted in India. Financial results for all the periods presented have been prepared in accordance with the recognition and measurement principles of IND AS 34.
9. Reconciliation between financial results as previously reported (referred to as "Previous GAAP") and Ind AS for quarter and nine months ended December 31, 2015 are as under:


(Rs. in crores)

Particulars	Standalone		Consolidated	
	Quarter ended 31.12.2015	Nine months ended 31.12.2015	Quarter ended 31.12.2015	Nine months ended 31.12.2015
Net profit as per Previous GAAP	15.11	63.96	46.93	121.20
Impact of Foreign Exchange on Long Term Foreign Currency Monetary Items	0.30	-1.01	0.30	-1.01
Depreciation impact on account of Fair Value Option, recognition of assets retirement obligation and change in classification of Leases.	-0.04	-0.13	-1.20	-6.41
Others	0.65	0.89	-1.27	-1.29
Net Profit for the period under Ind AS	17.02	63.71	44.76	112.49
Other Comprehensive Income	-0.08	1.39	21.99	23.28
Total Comprehensive Income under Ind AS	16.94	65.10	66.75	135.77



10. The Board of Directors has declared payment of interim dividend @ 60% on the paid up equity share capital of Rs.32,27,88,544/- (i.e. Rs.1.20/- per equity share of Rs.2/- each) for the Financial Year 2016-17 and 21st February, 2017 has been fixed as Record Date for the purpose of Payment of Interim Dividend for the financial year 2016-17.
11. The Hon'ble High Court of Gujarat has passed the Order sanctioning the Scheme of Arrangement and Amalgamation amongst Dishman Pharmaceuticals and Chemicals Ltd., Carbogen Amcis (India) Limited and Dishman Care Limited and their respective Shareholders & Creditors ("Scheme") on 16th December, 2016, which is made available on the website of Hon'ble High Court of Gujarat on 19th December, 2016. The Company is awaiting the receipt of the certified copy of the said order along with certified copy of the Scheme from the Hon'ble High Court of Gujarat. The Scheme will come into effect upon filing certified true copy of order alongwith Scheme with the Registrar of Companies, Gujarat [ROC]. Pending filing with ROC, no impact of Scheme has been given in books of account.
12. As certain assets of the company including manufacturing facilities, development facilities and financial assets and liabilities are often deployed interchangeably across segment, it is impractical to allocate these assets and liabilities to each segment. Hence, the details for capital employed have not been disclosed in the above table.
13. Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, the aforesaid financial Result may be accessed on the Company's website at www.dishmangroup.com and may also be accessed at the website of the Stock Exchanges where the shares of the Company are listed at www.bseindia.com and www.nseindia.com.
14. The previous period figures have been re-grouped, re-cast and re-arranged wherever considered necessary;

Place: Ahmedabad
Date: 13th February, 2017



On behalf of the Board of Directors


Arpit Vyas
Managing Director & CFO
DIN - 01540057

